कोशिश गोल्ड - मुक्त

TECH-POWERED WAR ON AMR

BioSpectrum Asia

|

July 2023

The consistent increase in antimicrobial resistance (AMR) is threatening to undo many of the gains of modern medicine. The situation is particularly alarming in the Asia Pacific region, which could witness around 50 per cent of global annual AMR-related mortality by 2050. Around 62 per cent of antibiotics in the region are used without prescriptions, indicating inappropriate usage and significantly increasing the risk of AMR strain emergence, according to a report from LEK Consulting Group. All this makes the region an epicentre of AMR and its consequences. In response to the growing threat, countries in the region have taken steps to tackle the AMR threat. These include a National Action Plan on AMR (NAP-AMR), antimicrobial stewardship efforts, diagnostics surveillance etc. However, the million-dollar question is whether these steps will be effective and enough. Let’s find out.

- Ayesha Siddiqui

TECH-POWERED WAR ON AMR

I 'n 2022, the World Health Organisation SouthEast Asia Region (WHO SEAR) released the third progress analysis of implementing NAPS to address AMR. The analysis reveals that all eleven member states in the region made progress against the NAP-AMR between 2018 and 2021, with Bhutan, Korea, and Thailand leading the way. These achievements occurred despite the challenges posed by the COVID-19 pandemic. The implementation of NAP-AMR in all countries of the region reached 64 per cent progress, a significant improvement compared to 40 per cent recorded in the second situational analysis in 2018. Furthermore, there were no reported regressions in implementation status during 2021, as compared to the 2018 analysis. Many innovative approaches and technologies are being deployed against the AMR scourge.

There have been incremental steps taken to address this monumental crisis. Experts, however, believe that the progress made so far is not enough given the severity of the situation.

Sharing his views on the steps taken John Alter, Head of external affairs at the AMR Action Fund

BioSpectrum Asia से और कहानियाँ

BioSpectrum Asia

BioSpectrum Asia

"The next 5-years will see mRNA science evolve beyond infectious disease"

A new survey from Moderna Singapore reveals persistent vaccine hesitancy among older adults in Singapore, even as international travel and year-end gatherings increase the urgency of protection. The findings point to clear opportunities to strengthen public health, including empowering healthcare professionals as trusted messengers and promoting co-administration of vaccines.

time to read

4 mins

BioSpectrum Asia Dec 2025

BioSpectrum Asia

No Funding No Vax for TB?

The World Health Organization (WHO)'s latest updates on tuberculosis (TB) released on November 12 reveal significant progress in diagnosis, treatment, and political commitment, but also expose deep vulnerabilities—especially in the South-East Asia Region (SEARO)—related to funding gaps and the uncertain future of novel TB vaccines. SEARO remains the global epicentre of the TB epidemic, carrying more than 45 per cent of the world's TB incidence despite representing only a quarter of the global population.

time to read

2 mins

BioSpectrum Asia Dec 2025

BioSpectrum Asia

BioSpectrum Asia

Australia builds tailored heart pump to transform heart failure care

Despite making up half of the 64 million people living with heart failure, patients with this common form have no access to heart pump treatments and are left with only medication or palliative care.

time to read

1 min

BioSpectrum Asia Dec 2025

BioSpectrum Asia

BioSpectrum Asia

Clinical Research Trends 2026: Hybrid DCTs Set for Surge as Innovation Outpaces Regulatory Hurdles

APAC's openness to innovation, combined with its large population and low trial density, creates strong potential for expanding decentralised clinical trials (DCTs), especially for patients with limited trial access. While regulatory diversity and operational challenges will continue to hinder fully decentralised models, the region is expected to adopt more digital technologies in clinical research. As a result, hybrid DCTs will keep gaining traction, and effective management of digitally collected data will remain a central focus for data science teams.

time to read

4 mins

BioSpectrum Asia Dec 2025

BioSpectrum Asia

BioSpectrum Asia

CSL Seqirus to localise advanced influenza vaccine manufacturing in Saudi Arabia

Australia-based CSL Seqirus and Vaccine Industrial Company have signed a Memorandum of Understanding with the Ministry of Health of Saudi Arabia to enhance the biotechnology sector by accessing advanced cellbased seasonal and pandemic influenza vaccines and localising manufacturing in Saudi Arabia.

time to read

1 min

BioSpectrum Asia Dec 2025

BioSpectrum Asia

BioSpectrum Asia

How Sponsors Could Gain Advantage by Embracing Dose Optimisation in Asia by 2026

In 2026, oncology drug development in Asia may move away from the historical maximum tolerated dose (MTD) paradigm toward evidence-based dose optimisation. Sponsors might consider adopting strategies similar to the FDA's Project Optimus, which emphasises selecting doses that balance efficacy and safety rather than relying solely on toxicity thresholds. Doing so could improve patient outcomes and position companies favourably as regulatory expectations evolve.

time to read

1 mins

BioSpectrum Asia Dec 2025

BioSpectrum Asia

BioSpectrum Asia

Fujifilm launches joint research with National Cancer Center in Japan

Fujifilm Corporation has signed a joint research agreement with the National Cancer Center Japan, a Tokyo-based national institution recognised for its leadership in cancer care and research.

time to read

1 min

BioSpectrum Asia Dec 2025

BioSpectrum Asia

BioSpectrum Asia

Monash spinout RAGE Biotech secures $29 M to advance next-generation RNA therapeutics

Australia's Monash University spinout RAGE Biotech has raised $29 million in Series A funding, marking a major step toward translating RNA-based therapeutics for chronic inflammatory disease into the clinic.

time to read

1 min

BioSpectrum Asia Dec 2025

BioSpectrum Asia

BioSpectrum Asia

Submitting clinical data to the FDA and PDMA: An efficient and compliant approach

In both the US and Japan, regulators provide an extensive set of resources detailing the rules and specifications governing submissions for marketing approval of new drugs and biologics. Fortunately, despite some differences, the regulations concerning clinical data have a surprising amount in common. It is possible that with a solid understanding of the requirements and an adherence to best practices, sponsors can develop some of the same material for submission to both countries.

time to read

2 mins

BioSpectrum Asia Dec 2025

BioSpectrum Asia

BioSpectrum Asia

Regenerative medicines and microbiome health are emerging as exciting frontiers, with Australian companies and researchers pushing into new therapeutic approaches

After more than a year at the helm of AusBiotech, CEO Rebekah Cassidy reflects on her early priorities and the organisation’s ambitions as Australia accelerates its position in the global life sciences economy. In an email interaction on the sidelines of AusBiotech 2025, she highlights the country's progress in mRNA, cell and gene therapy, and radiopharmaceuticals, outlines emerging areas of momentum, and discusses how new partnerships and MoUs are strengthening collaboration across the biotech ecosystem. Rebekah also outlines how AusBiotech is preparing Australia for a more competitive and connected global life sciences economy and the strategic priorities shaping AusBiotech’s next chapter. Edited excerpts:

time to read

7 mins

BioSpectrum Asia Dec 2025

Translate

Share

-
+

Change font size